TGTX Overview

TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.

Wall Street analysts forecast TGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TGTX is43.50 USD with a low forecast of 15.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

TG Therapeutics Inc revenue for the last quarter amounts to 204.92M USD, increased 69.56

TG Therapeutics Inc. EPS for the last quarter amounts to 0.12 USD, increased 300.00

TG Therapeutics Inc (TGTX) has 399 emplpoyees as of June 18 2026.

Today TGTX has the market capitalization of 7.88B USD.